375 related articles for article (PubMed ID: 26615564)
1. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
[TBL] [Abstract][Full Text] [Related]
2. External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience.
Griguolo G; Jacot W; Kantelhardt E; Dieci MV; Bourgier C; Thomssen C; Bailleux C; Miglietta F; Braccini AL; Conte P; Ferrero JM; Guarneri V; Darlix A
Breast; 2018 Feb; 37():36-41. PubMed ID: 29073498
[TBL] [Abstract][Full Text] [Related]
3. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
Kuba S; Ishida M; Nakamura Y; Yamanouchi K; Minami S; Taguchi K; Eguchi S; Ohno S
Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery.
Vern-Gross TZ; Lawrence JA; Case LD; McMullen KP; Bourland JD; Metheny-Barlow LJ; Ellis TL; Tatter SB; Shaw EG; Urbanic JJ; Chan MD
J Neurooncol; 2012 Dec; 110(3):381-8. PubMed ID: 23001361
[TBL] [Abstract][Full Text] [Related]
6. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
[TBL] [Abstract][Full Text] [Related]
8. Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases.
Dyer MA; Kelly PJ; Chen YH; Pinnell NE; Claus EB; Lee EQ; Weiss SE; Arvold ND; Lin NU; Alexander BM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e479-86. PubMed ID: 22704705
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer brain metastases - A 12 year review of treatment outcomes.
De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and survival outcome in cerebral metastatic breast cancer.
Bachmann C; Schmidt S; Staebler A; Schittenhelm J; Wallwiener D; Grischke EM
Med Oncol; 2014 Mar; 31(3):862. PubMed ID: 24504842
[TBL] [Abstract][Full Text] [Related]
12. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
Sperduto PW; Kased N; Roberge D; Chao ST; Shanley R; Luo X; Sneed PK; Suh J; Weil RJ; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
J Neurooncol; 2013 May; 112(3):467-72. PubMed ID: 23462853
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract][Full Text] [Related]
14. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Figura NB; Potluri TK; Mohammadi H; Oliver DE; Arrington JA; Robinson TJ; Etame AB; Tran ND; Liu JK; Soliman H; Forsyth PA; Sahebjam S; Yu HM; Han HS; Ahmed KA
J Neurooncol; 2019 Sep; 144(3):583-589. PubMed ID: 31399935
[TBL] [Abstract][Full Text] [Related]
15. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Yomo S; Hayashi M; Cho N
J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
[TBL] [Abstract][Full Text] [Related]
16. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
Zhang T; Li Q; Xu B; Zhang P; Yuan P; Ma F; Wang J; Fan Y
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
18. Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation.
Wilkinson JB; Shah C; Amin M; Nadeau L; Shaitelman SF; Chen PY; Grills IS; Martinez AA; Mitchell CK; Wallace MF; Vicini FA
Clin Breast Cancer; 2017 Feb; 17(1):55-60. PubMed ID: 27666436
[TBL] [Abstract][Full Text] [Related]
19. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
20. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
